Prediagnostic Plasma Bile Acid Levels and Colon Cancer Risk: A Prospective Study.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
01 05 2020
01 05 2020
Historique:
received:
11
02
2019
revised:
24
07
2019
accepted:
14
08
2019
pubmed:
23
8
2019
medline:
9
1
2021
entrez:
23
8
2019
Statut:
ppublish
Résumé
Bile acids have been proposed to promote colon carcinogenesis. However, there are limited prospective data on circulating bile acid levels and colon cancer risk in humans. Associations between prediagnostic plasma levels of 17 primary, secondary, and tertiary bile acid metabolites (conjugated and unconjugated) and colon cancer risk were evaluated in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Bile acid levels were quantified by tandem mass spectrometry in samples from 569 incident colon cancer cases and 569 matched controls. Multivariable logistic regression analyses were used to estimate odds ratios (ORs) for colon cancer risk across quartiles of bile acid concentrations. Positive associations were observed between colon cancer risk and plasma levels of seven conjugated bile acid metabolites: the primary bile acids glycocholic acid (ORquartile 4 vs quartile 1= 2.22, 95% confidence interval [CI] = 1.52 to 3.26), taurocholic acid (OR = 1.78, 95% CI = 1.23 to 2.58), glycochenodeoxycholic acid (OR = 1.68, 95% CI = 1.13 to 2.48), taurochenodeoxycholic acid (OR = 1.62, 95% CI = 1.11 to 2.36), and glycohyocholic acid (OR = 1.65, 95% CI = 1.13 to 2.40), and the secondary bile acids glycodeoxycholic acid (OR = 1.68, 95% CI = 1.12 to 2.54) and taurodeoxycholic acid (OR = 1.54, 95% CI = 1.02 to 2.31). By contrast, unconjugated bile acids and tertiary bile acids were not associated with risk. This prospective study showed that prediagnostic levels of certain conjugated primary and secondary bile acids were positively associated with risk of colon cancer. Our findings support experimental data to suggest that a high bile acid load is colon cancer promotive.
Sections du résumé
BACKGROUND
Bile acids have been proposed to promote colon carcinogenesis. However, there are limited prospective data on circulating bile acid levels and colon cancer risk in humans.
METHODS
Associations between prediagnostic plasma levels of 17 primary, secondary, and tertiary bile acid metabolites (conjugated and unconjugated) and colon cancer risk were evaluated in a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Bile acid levels were quantified by tandem mass spectrometry in samples from 569 incident colon cancer cases and 569 matched controls. Multivariable logistic regression analyses were used to estimate odds ratios (ORs) for colon cancer risk across quartiles of bile acid concentrations.
RESULTS
Positive associations were observed between colon cancer risk and plasma levels of seven conjugated bile acid metabolites: the primary bile acids glycocholic acid (ORquartile 4 vs quartile 1= 2.22, 95% confidence interval [CI] = 1.52 to 3.26), taurocholic acid (OR = 1.78, 95% CI = 1.23 to 2.58), glycochenodeoxycholic acid (OR = 1.68, 95% CI = 1.13 to 2.48), taurochenodeoxycholic acid (OR = 1.62, 95% CI = 1.11 to 2.36), and glycohyocholic acid (OR = 1.65, 95% CI = 1.13 to 2.40), and the secondary bile acids glycodeoxycholic acid (OR = 1.68, 95% CI = 1.12 to 2.54) and taurodeoxycholic acid (OR = 1.54, 95% CI = 1.02 to 2.31). By contrast, unconjugated bile acids and tertiary bile acids were not associated with risk.
CONCLUSIONS
This prospective study showed that prediagnostic levels of certain conjugated primary and secondary bile acids were positively associated with risk of colon cancer. Our findings support experimental data to suggest that a high bile acid load is colon cancer promotive.
Identifiants
pubmed: 31435679
pii: 5552558
doi: 10.1093/jnci/djz166
pmc: PMC7225675
doi:
Substances chimiques
Bile Acids and Salts
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
516-524Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 25004
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Curr Top Med Chem. 2012;12(6):625-36
pubmed: 22242858
Gastroenterology. 1993 Jan;104(1):145-51
pubmed: 8419237
Eur J Nutr. 2018 Feb;57(1):1-24
pubmed: 28393285
PLoS One. 2016 Apr 19;11(4):e0153959
pubmed: 27092559
Trends Mol Med. 2011 Oct;17(10):564-72
pubmed: 21724466
Curr Opin Gastroenterol. 2014 May;30(3):332-8
pubmed: 24625896
Int J Food Sci Nutr. 2009;60 Suppl 6:116-25
pubmed: 19499433
Br J Cancer. 2002 Jun 5;86(11):1741-4
pubmed: 12087460
Yonsei Med J. 2008 Oct 31;49(5):792-803
pubmed: 18972600
Oncotarget. 2017 Dec 1;8(70):115736-115747
pubmed: 29383197
J Lipid Res. 2006 Feb;47(2):241-59
pubmed: 16299351
Cancer. 2014 Oct 1;120(19):3049-57
pubmed: 24894841
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jan 1;878(1):51-60
pubmed: 19945922
Nat Rev Endocrinol. 2014 Aug;10(8):488-98
pubmed: 24821328
Curr Nutr Rep. 2017 Dec;6(4):315-322
pubmed: 29430336
Mol Aspects Med. 2017 Aug;56:2-9
pubmed: 28153453
Nat Rev Microbiol. 2014 Oct;12(10):661-72
pubmed: 25198138
Int J Epidemiol. 1997;26 Suppl 1:S6-14
pubmed: 9126529
Public Health Nutr. 2003 Jun;6(4):407-13
pubmed: 12795830
N Engl J Med. 2018 Aug 30;379(9):888-890
pubmed: 30157405
Gut. 1995 Feb;36(2):268-73
pubmed: 7883228
J Lipid Res. 2012 Oct;53(10):2231-41
pubmed: 22822028